Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Enrique Zudaire"'
Autor:
Enriqueta Felip, Victor Moreno, Daniel Morgensztern, Giuseppe Curigliano, Piotr Rutkowski, José Manuel Trigo, Aitana Calvo, Dariusz Kowalski, Diego Cortinovis, Ruth Plummer, Michele Maio, Paolo A. Ascierto, Vladimir I. Vladimirov, Andres Cervantes, Enrique Zudaire, Anasuya Hazra, Huybrecht T’jollyn, Nibedita Bandyopadhyay, James G. Greger, Edward Attiyeh, Hong Xie, Emiliano Calvo
Publikováno v:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
Purpose To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the
Autor:
Kuo-Sheng Hsu, James M. Dunleavey, Christopher Szot, Liping Yang, Mary Beth Hilton, Karen Morris, Steven Seaman, Yang Feng, Emily M. Lutz, Robert Koogle, Francesco Tomassoni-Ardori, Saurabh Saha, Xiaoyan M. Zhang, Enrique Zudaire, Pradip Bajgain, Joshua Rose, Zhongyu Zhu, Dimiter S. Dimitrov, Frank Cuttitta, Nancy J. Emenaker, Lino Tessarollo, Brad St. Croix
Collagen I, the most abundant protein in humans, is ubiquitous in solid tumors where it provides a rich source of exploitable metabolic fuel for cancer cells. While tumor cells were unable to exploit collagen directly, here we show they can usurp met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5002c0cac5a42652a88fb48cefed902e
https://doi.org/10.21203/rs.3.rs-1451724/v1
https://doi.org/10.21203/rs.3.rs-1451724/v1
Autor:
Mathieu Marella, Xiang Yao, Vinicius Carreira, Marta F. Bustamante, H. Brent Clark, Carolyn C. Jackson, Enrique Zudaire, Jordan M. Schecter, Tynisha D. Glover, Jacintha Shenton, Ingrid Cornax
Publikováno v:
J Histochem Cytochem
B-cell maturation antigen (BCMA) is a target for the treatment of multiple myeloma with cytolytic therapies, such as chimeric antigen receptor T-cells or T-cell redirecting antibodies. To better understand the potential for “on-target/off-tumor”
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2aab657a4b23cf6ef58b8827699f46a
https://europepmc.org/articles/PMC8971684/
https://europepmc.org/articles/PMC8971684/
Autor:
Adam D. Cohen, Samir Parekh, Bianca D. Santomasso, Jaime Gállego Pérez-Larraya, Niels W. C. J. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carolyn C. Jackson, Kevin C. De Braganca, Jordan M. Schecter, Loreta Marquez, Erin Lee, Ingrid Cornax, Enrique Zudaire, Claire Li, Yunsi Olyslager, Deepu Madduri, Helen Varsos, Lida Pacaud, Muhammad Akram, Dong Geng, Andrzej Jakubowiak, Hermann Einsele, Sundar Jagannath
Publikováno v:
Blood cancer journal, 12(2):32. Nature Publishing Group
Cohen, A D, Parekh, S, Santomasso, B D, Pérez-Larraya, J G L, van de Donk, N W C J, Arnulf, B, Mateos, M-V, Lendvai, N, Jackson, C C, de Braganca, K C, Schecter, J M, Marquez, L, Lee, E, Cornax, I, Zudaire, E, Li, C, Olyslager, Y, Madduri, D, Varsos, H, Pacaud, L, Akram, M, Geng, D, Jakubowiak, A, Einsele, H & Jagannath, S 2022, ' Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies ', Blood cancer journal, vol. 12, no. 2, 32 . https://doi.org/10.1038/s41408-022-00629-1
Cohen, A D, Parekh, S, Santomasso, B D, Pérez-Larraya, J G L, van de Donk, N W C J, Arnulf, B, Mateos, M-V, Lendvai, N, Jackson, C C, de Braganca, K C, Schecter, J M, Marquez, L, Lee, E, Cornax, I, Zudaire, E, Li, C, Olyslager, Y, Madduri, D, Varsos, H, Pacaud, L, Akram, M, Geng, D, Jakubowiak, A, Einsele, H & Jagannath, S 2022, ' Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies ', Blood cancer journal, vol. 12, no. 2, 32 . https://doi.org/10.1038/s41408-022-00629-1
Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients with MM reported movem
Autor:
Paul Kirschmeier, Jeffrey Liu, Andrew H. Beck, Catherine Ferrante, Sangeetha Palakurthi, Christopher Moy, Elena Ivanova, Mark A. Bittinger, Martha R. Gowaski, Abha Dhaneshwar, Dennis M. Bonal, Mari Kuraguchi, Matthew V. Lorenzi, Kwok-Kin Wong, Kristin Depeaux, Samuel N. Regan, Jessie M. English, Catherine Sanders, Raluca I. Verona, Julie A. Rytlewski, Pasi A. Jänne, Kathryn Packman, Dyane Bailey, Enrique Zudaire, Wei Huang, Sima Zacharek, Sylvie Laquerre, Aditya Khosla
Publikováno v:
Cancer Immunology Research. 7:1457-1471
The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor re
Autor:
Sen Hong Zhuang, Elizabeth O'Donnell, Syed Rizvi, Saad Z. Usmani, Myo Htut, Jenna D. Goldberg, Jesus G. Berdeja, Xiaoling Wu, Abhinav Deol, David Avigan, Andrzej Jakubowiak, Jordan M. Schecter, Dong Geng, Muhammad Akram, Parameswaran Hari, William Deraedt, Indrajeet Singh, Farah Hossain, Deepu Madduri, Sundar Jagannath, Tzu-Min Yeh, Mounzer Agha, Jeffrey R. Infante, Carolyn C. Jackson, Nikhil C. Munshi, Alicia J. Allred, Frank Fan, Marlene J Carrasco-Alfonso, A. Keith Stewart, Arnob Banerjee, Yi Lin, Enrique Zudaire, Yunsi Olyslager, Alexander M. Lesokhin, Adam D. Cohen, Thomas Martin
Publikováno v:
Lancet (London, England). 398(10297)
Summary Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients wi
Autor:
Charles G, Drake, Russell K, Pachynski, Sumit K, Subudhi, Douglas G, McNeel, Emmanuel S, Antonarakis, Todd M, Bauer, Peter, Lauer, Dirk, Brockstedt, Daniel, Patricia, Mark, Wade, Enrique, Zudaire, Nibedita, Bandyopadhyay, Dolly A, Parasrampuria, Suzette, Girgis, Gary E, Mason, Roland E, Knoblauch, Nicole, Stone, Jeffrey R, Infante, Marco M, Gottardis, Lawrence, Fong
Publikováno v:
Prostate cancer and prostatic diseases. 25(2)
The safety and immunogenicity of JNJ-64041809 (JNJ-809), a live-attenuated, double-deleted Listeria monocytogenes (LADD Lm)-based immunotherapy targeting 4 relevant prostate cancer antigens, was evaluated in a phase 1 study in patients with metastati
Autor:
Xu-Chao Zhang, Xiayu Huang, Zayed Albertyn, Suso Platero, Yang Qiu, Matthew V. Lorenzi, Jun Wang, Jennifer Yang, Jingyu Zhang, Enrique Zudaire, Bo Wang, Qun Wang, Xiaotao Qu, Ying Cheng, Yi-Long Wu, Lin Xu, Guo-Guang Shao, Christopher Moy, Yue Fan
Publikováno v:
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Deep understanding of the genomic and immunological differences between Chinese and Western lung cancer patients is of great importance for target therapy selection and development for Chinese patients. Here we report an extensive molecular and immun
Autor:
Bofan Wu, Steven Seaman, Enrique Zudaire, Jeffrey S. Rubin, Ming Zhou, Holly Morris, Animesh Shukla, Brad St. Croix, Ekaterina Posokhova, Suresh R. Volate, Mary Beth Hilton, Deborah A. Swing
Publikováno v:
Cell Reports, Vol 10, Iss 2, Pp 123-130 (2015)
SummaryG protein-coupled receptor 124 (GPR124) is an orphan receptor in the adhesion family of GPCRs, and previous global or endothelial-specific disruption of Gpr124 in mice led to defective CNS angiogenesis and blood-brain barriergenesis. Similar d
Autor:
Sylvia Degrado, Kimberly D. Klarmann, Dimiter S. Dimitrov, Julia Scheiermann, Brad St. Croix, Zhongyu Zhu, Dmitry Borkin, Yang Feng, Steven Seaman, Mi Young Yang, Enrique Zudaire, Holly Morris, Yanping Wang, Nareshkumar F. Jain, Karen Morris, Jinyu Li, Mary Beth Hilton, Sean W. Smith, Jonathan R. Keller, Lino Tessarollo, Saurabh Saha, Christopher S. Szot, Amit Chaudhary, Deborah A. Swing, Xiaoyan M. Zhang, Decrescenzo Gary A, Dean Welsch
Publikováno v:
Cancer cell. 31(4)
Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a promising anti-cancer strategy that in order to be realized must overcome several obstacles, including identification of suitable targets and optimal warheads. Here, we demonst